SCHEMBL2408480

SCHEMBL2408480

CC(C)(C)OC(=O)C(C)(C)Sc1nc(CC(=O)Nc2ccc(Br)cc2)cs1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ TP53 P04637 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ LMNA P02545 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ CTPS1 P17812 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ THRB P10828 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ FPR3 P25089 1/20 0.38
▸ FPR2 P25090 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412085 0.87 ALDH1A1 (0.43) MAPTSMN1; SMN2GAAMEN1KMT2A
SCHEMBL2410029 0.85 LMNA (0.54) MAPTTP53SMN1; SMN2GAALMNA
SCHEMBL2413278 0.80 MEN1 (0.40) MAPTTP53SMN1; SMN2GAAMEN1
SCHEMBL12275540 0.80 SMN1; SMN2 (0.46) MAPTTP53SMN1; SMN2GAAMEN1
SCHEMBL2410572 0.79 SMN1; SMN2 (0.40) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL2410840 0.79 L3MBTL1 (0.34) MAPTTP53SMN1; SMN2GAAKMT2A
SCHEMBL12274759 0.79 MEN1 (0.52) MAPTTP53SMN1; SMN2GAAMEN1
SCHEMBL2414685 0.79 HSD17B10 (0.43) MAPTSMN1; SMN2GAALMNAHPGD
SCHEMBL2409605 0.77 MEN1 (0.57) MAPTTP53SMN1; SMN2GAAMEN1
SCHEMBL2412445 0.77 SMN1; SMN2 (0.48) MAPTTP53SMN1; SMN2GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG MAPT 3435/4885TP53 2553/4885SMN1; SMN2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback